8-K

                                    FORM 8-K

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                              WASHINGTON, DC 20549

                                 CURRENT REPORT

                       Pursuant to Section 13 or 15(d) of
                       the Securities Exchange Act of 1934


       Date of Report (Date of earliest event reported): January 13, 2005

                           DUSA PHARMACEUTICALS, INC.
             (Exact name of registrant as specified in its charter)


     NEW JERSEY                         0-19777                 22-3103129
   (State or other                                            (IRS Employer
   jurisdiction of                    (Commission            Identification
   incorporation)                     File Number)               Number)


                                 25 UPTON DRIVE
                         WILMINGTON, MASSACHUSETTS 01887
          (Address of principal executive offices, including ZIP code)

                                 (978) 657-7500
              (Registrant's telephone number, including area code)


Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

[ ]  Written communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)

[ ]  Soliciting material pursuant to Rule 14a-12 under the Securities Act
(17 CFR 240.14a-12)

[ ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14a-12(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR 240.13e-4(c))








ITEM 8.01.   OTHER EVENTS.

DUSA Pharmaceuticals, Inc. ("DUSA") issued a press release on January 13, 2005
attached to and made part of this report, announcing increased fourth quarter
(Q4) and full year Levulan(R) Kerastick(R) end-user sales, along with Q4 and
full year 2004 BLU-U(R) placements.

Except for historical information, this report contains certain forward-looking
statements that involve known and unknown risks and uncertainties, which may
cause actual results to differ materially from any future results, performance
or achievements expressed or implied by the statements made. These
forward-looking statements relate to the expectations for the timing of receipt
of BLU-U inventory and performance for 2005. Such risks and uncertainties
include, but are not limited to, dependence on third-party manufacturers, the
Company's ability to continue to penetrate the market, maintenance of its patent
portfolio, and other risks identified in our SEC filings from time to time,
including those contained in DUSA's Form 10-K for the year ended December 31,
2003.



ITEM 9.01.   FINANCIAL STATEMENT AND EXHIBITS.

99       Press Release dated January 13, 2005







                                   SIGNATURES


         Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.


                                         DUSA PHARMACEUTICALS, INC.






Dated:  January 13, 2005                 By: /s/ D. Geoffrey Shulman
                                            ----------------------------------
                                            D. Geoffrey Shulman, MD, FRCPC
                                            Chairman of the Board and Chief
                                            Executive Officer









                                  EXHIBIT INDEX

99       Press Release dated January 13, 2005

EX-99

                                                                      EXHIBIT 99

[DUSA LOGO]
INNOVATION IN PHOTODYNAMIC THERAPY

DUSA PHARMACEUTICALS, INC. (R)

FOR RELEASE AT 8:00 A.M.


                DUSA ANNOUNCES INCREASED FOURTH QUARTER AND 2004
                     LEVULAN(R) KERASTICK(R) END-USER SALES

WILMINGTON, MA. JANUARY 13, 2005 - DUSA Pharmaceuticals, Inc. (NASDAQ NMS: DUSA)
today announced increased fourth quarter (Q4) and full year Levulan(R)
Kerastick(R) end-user sales, along with Q4 and full year 2004 BLU-U(R)
placements.

For Q4 2004, end-user Kerastick sales to physicians totaled 26,322, consisting
of 22,944 sold in the United States (US), and 3,378 sold by Coherent-AMT, our
Canadian marketing and distribution partner. During Q3 2004, Kerastick sales
totaled 20,196, including 18,870 in the US and 1,326 in Canada. During Q4 2003,
US Kerastick sales totaled 5,478, with no sales in Canada at that time.

For full-year 2004, 76,482 Kerastick units were sold, including 69,870 in the US
and 6,612 in Canada, versus a total of 11,172 sold during 2003, all in the US.

In percentage terms, 2004 Kerastick sales growth from Q3 to Q4 was 30% in total
and 22% in the US versus 13% sales growth in total and 18% in the US from Q2 to
Q3 2004. Q4 2004 sales vs. Q4 2003 sales were up by 381%, while overall 2004
sales were up 585% vs. 2003 total sales.

The net number of BLU-U units placed in doctors' offices during the fourth
quarter was 44, consisting of 29 in the US and 15 in Canada. For the full year
2004, 508 BLU-U units (net) were placed and a total of 914 units were in
doctor's offices by the end of 2004, consisting of 813 in the US and 101 in
Canada, versus 406 at the end of 2003, all of which were installed in the US. As
announced previously, BLU-U sales during Q4 were expected to be modest due to
inventory supply constraints. We have ordered additional BLU-Us, and expect to
be re-supplied prior to the annual meeting of the American Academy of
Dermatology in mid-February, 2005.

Dr. D. Geoffrey Shulman, DUSA's Chairman and CEO, stated "We are very pleased by
the strong quarterly and annual growth in Kerastick sales, reflecting the
increasing interest in, and demand for, our therapy. Based on these trends, we
are looking forward to making 2005 another successful year."

DUSA Pharmaceuticals, Inc. is a biopharmaceutical company engaged primarily in
the development of Levulan Photodynamic Therapy (PDT) and Photodetection (PD)
for multiple medical conditions, with its primary focus in dermatology. PDT and
PD utilize light-activated compounds to induce a therapeutic or detection
effect. DUSA maintains offices in Wilmington, MA, Valhalla, NY and Toronto,
Ontario.








Except for historical information, this news release contains certain
forward-looking statements that involve known and unknown risks and
uncertainties, which may cause actual results to differ materially from any
future results, performance or achievements expressed or implied by the
statements made. These forward-looking statements relate to the expectations for
the timing of receipt of BLU-U inventory and performance for 2005. Such risks
and uncertainties include, but are not limited to, dependence on third-party
manufacturers, the Company's ability to continue to penetrate the market,
maintenance of its patent portfolio, and other risks identified in our SEC
filings from time to time, including those contained in DUSA's Form 10-K for the
year ended December 31, 2003.

For further information contact:
D. GEOFFREY SHULMAN, MD, Chairman and CEO
or SHARI LOVELL, Director, Shareholder Services Tel: 416.363.5059
Fax: 416.363.6602 or visit www.dusapharma.com